The Complete Clinical Pharmacology of Growth Hormone and Its Secretagogues
This comprehensive review covers GH pharmacology from pituitary regulation to clinical applications of GH and secretagogues (GHRP, MK-677) for GH deficiency, aging, obesity, and critical illness.
Quick Facts
What This Study Found
GH secretagogues (GHRP-6, hexarelin, MK-677) offer clinical advantages over GH injections: oral availability, physiological pulsatile release patterns, and multiple applications from GH deficiency to aging, obesity, and critical illness.
Key Numbers
How They Did This
Comprehensive clinical pharmacology review covering GH biology, regulation, GH secretagogue pharmacology, and clinical applications across multiple indications.
Why This Research Matters
This serves as the definitive clinical pharmacology reference for practitioners and researchers working with GH and GH secretagogues across all therapeutic applications.
The Bigger Picture
The clinical landscape for GH therapy is evolving from daily injections to oral secretagogues. This review maps the complete pharmacology guiding this transition.
What This Study Doesn't Tell Us
Review from 2002. Some clinical applications were still in development. Long-term safety data for chronic GH secretagogue use was limited.
Questions This Raises
- ?Will oral GH secretagogues be approved for GH deficiency?
- ?Which clinical application offers the best risk-benefit profile?
- ?How should chronic GH secretagogue therapy be monitored?
Trust & Context
- Key Stat:
- Comprehensive reference Covers all GH secretagogues (GHRP, hexarelin, ipamorelin, MK-677) across all clinical applications — the complete clinical pharmacology guide
- Evidence Grade:
- Strong evidence from a comprehensive clinical pharmacology review integrating basic science with clinical trial data.
- Study Age:
- Published in 2002. Remains a valuable reference though the GH secretagogue field has continued to develop.
- Original Title:
- Clinical pharmacology of human growth hormone and its secretagogues.
- Published In:
- Current drug targets. Immune, endocrine and metabolic disorders, 2(1), 27-52 (2002)
- Authors:
- Root, Allen W, Root, Michael J
- Database ID:
- RPEP-00762
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What GH secretagogues are available?
Major compounds include GHRP-6, GHRP-2, hexarelin, ipamorelin, and MK-677. They differ in selectivity, route (injectable vs oral), and side effect profiles. MK-677 is the most advanced oral option.
Are GH secretagogues better than GH injections?
They offer potential advantages: oral dosing (MK-677), more natural GH release patterns, and the body's own feedback regulation. Whether they fully match GH injection efficacy for all conditions is still being determined.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00762APA
Root, Allen W; Root, Michael J. (2002). Clinical pharmacology of human growth hormone and its secretagogues.. Current drug targets. Immune, endocrine and metabolic disorders, 2(1), 27-52.
MLA
Root, Allen W, et al. "Clinical pharmacology of human growth hormone and its secretagogues.." Current drug targets. Immune, 2002.
RethinkPeptides
RethinkPeptides Research Database. "Clinical pharmacology of human growth hormone and its secret..." RPEP-00762. Retrieved from https://rethinkpeptides.com/research/root-2002-clinical-pharmacology-of-human
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.